Quantcast

Latest InspireMD Inc. Stories

2014-10-29 08:34:44

Validation of manufacturing process changes for the MGuard Prime EPS BOSTON, Oct. 29, 2014 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in Embolic Protection Systems (EPS), today announced that the FDA has approved the Company's submitted IDE amendment for certain manufacturing process changes to the MGuard Prime EPS that were proposed in response to the Company's April 30, 2014 Voluntary Field Action (VFA). InspireMD said while patient...

2014-10-14 08:31:28

MGuard Prime commercial re-launch complete in direct markets BOSTON, Oct. 14, 2014 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today provided commercial, development and clinical updates on the MGuard Prime coronary EPS product line and positioned the Company to address more efficiently its emerging MGuard and CGuard commercial opportunities. The Company indicated that it believes all...

2014-10-01 08:32:44

Commercial activities ahead of schedule following release of strong clinical data in the multi-specialty CARENET trial BOSTON, Oct. 1, 2014 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has recorded the first commercial sales of the CGuard(TM) carotid EPS. The Company accelerated the limited market release (LMR) of the CGuard based on strong interest created by the recent positive...

2014-09-18 16:27:51

CARENET Trial data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, September 16, 2014, showed 0% MACE at 30 Days BOSTON, Sept. 18, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), will host a live webinar and Q&A to discuss the positive results of its recent CARENET (CARotid Embolic protection study using microNET) Trial for its CGuard(TM) Embolic Protection System (EPS) which...

2014-09-03 08:34:19

BOSTON, Sept. 3, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), today announced that its Chief Financial Officer, Craig Shore, will be presenting at the Aegis Healthcare and Technology Conference at the Encore at Wynn Las Vegas. The Company will present on Friday, September 12, 2014 at 8:30 a.m. PT. A live webcast will be available for those participants who are unable to attend, which can be...

2014-08-11 08:28:58

Results will be announced on Tuesday, September 16 in Washington, D.C. BOSTON, Aug. 11, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), today announced that Professor Joachim Schofer, MD, at the Hamburg University Cardiovascular Center, will present the results of the CARENET (CARotid Embolic protection using microNET) trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference, in...

2014-07-17 08:29:39

BOSTON, July 17, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, announced today that it will release its financial results for the second quarter ended June 30, 2014 on Wednesday, July 23(rd). The Company will host a conference call at 4:30 p.m. ET on Wednesday, July 23(rd) to review its financial results and business outlook. Participants should call (877) 407-0784 (United States) or (201) 689-8560...

2014-07-15 08:28:52

Strengthens Leadership Team with Addition of Experienced Medical Device Executive BOSTON, July 15, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced the appointment of James Barry, Ph.D. as Chief Operating Officer. Barry, who has more than two decades of experience in the medical device industry, will be based in the Company's Boston headquarters. Dr. Barry will focus on three critical...

2014-07-08 08:31:38

100% procedural success rate achieved in first multi-specialty clinical experience BOSTON, July 8, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), today announced that it has concluded enrollment in its CARENET clinical trial. The multi-specialty (Interventional Cardiologists, Interventional Radiologists and Vascular Surgeons) trial is assessing the peri-procedural safety and efficacy of CGuard...

2014-07-01 08:30:24

BOSTON, July 1, 2014 /PRNewswire/ -- InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced that it has been selected to join the Russell Microcap Index, as of June 27, 2014. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective,...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related